Suppr超能文献

淋巴细胞膜和 12p1 双重功能化纳米颗粒,用于游离 HIV-1 的捕获和精准 siRNA 递送至 HIV-1 感染细胞。

Lymphocyte Membrane- and 12p1-Dual-Functionalized Nanoparticles for Free HIV-1 Trapping and Precise siRNA Delivery into HIV-1-Infected Cells.

机构信息

State key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics, Beijing Institute of Pharmacology and Toxicology, Beijing, 100039, China.

Pharmaceutical College, Henan University, Kaifeng, 475001, China.

出版信息

Adv Sci (Weinh). 2023 Apr;10(10):e2300282. doi: 10.1002/advs.202300282. Epub 2023 Feb 8.

Abstract

Despite the success of small interfering RNA (siRNA) in clinical settings and its potential value in human immunodeficiency virus (HIV) therapy, the rapid clearance and absence of precise delivery to target cells still hinder the therapeutic effect of siRNA. Herein, a new system, which can escape immune recognition, has HIV-1 neutralizing capacity, and the ability to deliver siRNA specifically into HIV-1-infected cells, is constructed by functionalizing siRNA delivery lipid nanoparticles with the lymphocyte membrane and 12p1. The constructed system is shown to escape uptake by the mononuclear phagocyte system. The constructed system exhibits strong binding ability with gp120, thus displaying distinguished neutralizing breadth and potency. The constructed system neutralizes all tested HIV-1 pseudotyped viruses with a geometric mean 80% inhibitory concentration (IC80) of 29.75 µg mL and inhibits X4-tropic HIV-1 with an IC80 of 64.20 µg mL , and R5-tropic HIV-1 with an IC80 of 16.39 µg mL . The new system also specifically delivers siRNA into the cytoplasm of HIV-1-infected cells and exhibits evident gene silencing of tat and rev. Therefore, this new system can neutralize HIV-1 and deliver siRNA selectively into HIV-1-infected cells and may be a promising therapeutic candidate for the precise therapy of HIV.

摘要

尽管小干扰 RNA(siRNA)在临床环境中的成功及其在人类免疫缺陷病毒(HIV)治疗中的潜在价值,但由于其快速清除和缺乏精确递送至靶细胞的能力,仍然阻碍了 siRNA 的治疗效果。在此,通过将淋巴细胞膜和 12p1 功能化到 siRNA 递送脂质纳米颗粒上,构建了一种能够逃避免疫识别、具有 HIV-1 中和能力且能够将 siRNA 特异性递送至 HIV-1 感染细胞的新型系统。所构建的系统被证明能够逃避单核吞噬细胞系统的摄取。该构建系统与 gp120 具有很强的结合能力,从而表现出显著的中和广度和效力。所构建的系统中和所有测试的 HIV-1 假型病毒的几何平均 80%抑制浓度(IC80)为 29.75 µg mL ,抑制 X4 嗜性 HIV-1 的 IC80 为 64.20 µg mL ,抑制 R5 嗜性 HIV-1 的 IC80 为 16.39 µg mL 。该新型系统还可以特异性地将 siRNA 递送至 HIV-1 感染细胞的细胞质中,并表现出明显的 tat 和 rev 基因沉默。因此,这种新型系统可以中和 HIV-1 并选择性地将 siRNA 递送至 HIV-1 感染细胞,可能是 HIV 精确治疗的有前途的治疗候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ced3/10074117/e46d0ba731aa/ADVS-10-2300282-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验